All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsUNIVERSITY OF CALIFORNIA LOS ANGELES

UNIVERSITY OF CALIFORNIA LOS ANGELES

Projects attributed to UNIVERSITY OF CALIFORNIA LOS ANGELES within this analysis sample.

In This Analysis
Projects
3
NIH Funding
$2.3M
Projects(3)
ProjectPICategoryFunding
Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC
5R01CA279094-03
CZERNIN, JOHANNESBasic Research$1.2M
Reducing toxicity from prostate cancer radiotherapy through genetics and technology
5R37CA292795-02
KISHAN, AMAR UTherapeutics$721K
Targeting tumor microenvironment-mediated radiopharmaceutical therapy resistance in prostate cancer
1R21CA303173-01
ABT, EVAN ROBERTMedical Device$405K
See UNIVERSITY OF CALIFORNIA LOS ANGELES’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.